DFINE Clinical Resources

DFINE is committed to building scientific evidence to support the use of our products. To date, numerous studies have been presented at scientific meetings worldwide and published in peer-review journals that illuminate the advantages of radiofrequency (RF) tumor ablation therapy with the STARTM Tumor Ablation System. Moving forward the company continues to invest in clinical studies to further improve the quality of life for patients suffering from vertebral pathologies complicated by metastatic spinal tumors.